Celldex Therapeutics reported $-84.44M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.83B 130M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -84.44M 2.72M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Northwest Biotherapeutics USD -14.32M 481K Sep/2025
Pfizer USD 4.99B 340M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025